Why Teladoc’s latest earnings are drawing attention

Teladoc Health (TDOC) just reported quarterly revenue slightly above expectations, paired with weaker near term guidance but a larger full year outlook increase than sector peers, putting both growth and caution on investors’ radar.

The mixed earnings update appears to have given Teladoc’s share price a short term lift, with a 1 month share price return of 20.65% contrasting with a 1 year total shareholder return of negative 33.13%. This suggests recent momentum is building off a much weaker multi year backdrop.

If Teladoc’s move has you reassessing digital health, it could be a good moment to broaden your watchlist and look for other healthcare focused AI names via 36 healthcare AI stocks

With Teladoc shares still well below multi year highs, but recent returns and guidance shifts back in focus, the key question is whether the current price underestimates its virtual care potential or already reflects future growth.

Most Popular Narrative: 12.2% Overvalued

The most followed narrative pegs Teladoc Health’s fair value at $5.00, below the last close of $5.61, framing the recent rebound as potentially ahead of fundamentals.

Increasingly stringent global data privacy and cybersecurity regulations are set to further escalate compliance costs for Teladoc Health, raising the risk of legal exposure and compressed operating margins as more sensitive health data is collected through expanded AI-driven and international offerings.

Curious what kind of revenue trajectory, margin shift, and future earnings multiple need to line up to justify that $5.00 fair value and the bearish price band.

Result: Fair Value of $5.00 (OVERVALUED)

However, stronger international growth or better than expected traction in 24/7 Care and BetterHelp insurance could challenge the bearish case and reset expectations.

Another view: multiples suggest a different story

While the most popular narrative sees Teladoc Health as 12.2% overvalued at a fair value of $5.00, the market pricing tells a different story. The current P/S ratio of 0.4x is far below the US Healthcare Services industry at 2.1x, peers at 2.3x, and an estimated fair ratio of 1.9x. This points to a wide gap between sentiment and what the market could move toward over time. Is this simply compensation for execution and profitability risk, or a sign that expectations have swung too far the other way?

Next Steps

After all this, do you feel the story is leaning too positive or too cautious? Act while the details are fresh and weigh both sides with 3 key rewards and 1 important warning sign

Looking for more investment ideas?

Do not stop at one stock when a whole universe of ideas is a few clicks away, use the Simply Wall Street Screener to pressure test and upgrade your watchlist.

• Hunt for quality at a reasonable price by scanning 49 high quality undervalued stocks that combine fundamentals and market pessimism in potentially interesting ways.
• Prioritise resilience by reviewing 76 resilient stocks with low risk scores that score well on stability so wild swings do not dominate your portfolio.
• Spot fresh ideas early by checking the screener containing 27 high quality undiscovered gems that most investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.